The CADTH Scientific Advice Program is a voluntary, non-binding, and confidential fee-for-service consultation. Through this Program, pharmaceutical companies are provided with advice on their early drug development plans from a Canadian health technology assessment perspective.
COVID-19 Update Regarding Scientific Advice
In light of the COVID-19 pandemic, we’ve made some changes to our CADTH Scientific Advice Program activities. During this challenging and uncertain time, we recognize that clinical experts may not be available to participate in our projects. As input from Canadian clinical experts is key to producing high-quality and relevant advice, we’ve decided to temporarily hold off on confirming any new requests for Scientific Advice.
As the COVID-19 situation continues to evolve, we will carefully consider when to resume our normal CADTH Scientific Advice Program activities and will provide an update on our website: https://www.cadth.ca/scientific-advice.
During this time, we encourage prospective applicants to contact us directly to discuss proposed timelines at email@example.com. When activities resume, requests will be considered in the order that they were received.
Published : May 6, 2020